The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Henan Engineering Research Center for Tumor Precision Medicine and Comprehensive Evaluation, Henan Provincial Key Laboratory of Anticancer Drug Research, Zhengzhou 450008, China.
Comprehensive Utilization of Edible and Medicinal Plant Resources Engineering Technology Research Center, Zhengzhou Key Laboratory of Synthetic Biology of Natural Products, Henan Joint International Research Laboratory of Drug Discovery of Small Molecules, Huanghe Science and Technology College, Zhengzhou 450063, China.
J Immunol Res. 2022 Jul 28;2022:2931214. doi: 10.1155/2022/2931214. eCollection 2022.
Accumulating evidence has showed that sushi-repeat-containing protein X-linked 2 (SRPX2) is an abnormal expression in a variety of cancers and involved in cancer carcinogenesis, chemosensitivity, and prognosis, which mainly promote cancer cell metastasis, invasion, and migration by regulating the uPAR/integrins/FAK signaling pathway, epithelial-mesenchymal transition (EMT), angiogenesis, and glycosylation. Inflammation has been regarded as a key role in regulating cancer initiation, progression, EMT, and therapeutics. Furthermore, SRPX2 exhibited excellent antifibrosis effect the TGFR1/SMAD3/SRPX2/AP1/SMAD7 signaling pathway. Therefore, this review provides compelling evidence that SRPX2 might be a therapeutic target for inflammation and cancer-related inflammation for future cancer therapeutics.
越来越多的证据表明，X 连锁 sushi 重复蛋白 2（SRPX2）在多种癌症中异常表达，并参与癌症的发生、化疗敏感性和预后，主要通过调节 uPAR/整合素/FAK 信号通路、上皮间质转化（EMT）、血管生成和糖基化来促进癌细胞的转移、侵袭和迁移。炎症被认为是调节癌症发生、进展、EMT 和治疗的关键因素。此外，SRPX2 在 TGFβR1/SMAD3/SRPX2/AP1/SMAD7 信号通路中表现出优异的抗纤维化作用。因此，本综述提供了有力的证据，表明 SRPX2 可能成为未来癌症治疗中炎症和癌症相关炎症的治疗靶点。
